Testing effectiveness (Phase 2)Active Not RecruitingNCT05864742
What this trial is testing
Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma
Who this might be right for
Mantle Cell Lymphoma Refractory
Peter MacCallum Cancer Centre, Australia 40